RxDoctor Payments Data

Robert Monteiro, MD

Internal Medicine · Chapel Hill, NCNPI 1023001807

Payments from drug & device makers

$1,148in general payments, 2019–2025

Across 77 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$365
  • Abbott$197
  • Amgen$98
  • Johnson & Johnson$61
  • Daiichi Sankyo Inc.$58
  • Boehringer Ingelheim$43
  • plus $326 from 13 others

What the payments were for

  • Food & beverage$1,148100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,148 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$202,875
Medicare patients
371
Services billed
12,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$110,363
RybelsusSemaglutide86$101,330
JardianceEmpagliflozin53$73,366
MounjaroTirzepatide55$62,407
OzempicSemaglutide38$37,080
TrulicityDulaglutide33$33,431
JanuviaSitagliptin Phosphate30$23,785
XareltoRivaroxaban18$18,896
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$18,768
Breo ElliptaFluticasone/Vilanterol31$13,093
Repatha SureclickEvolocumab20$12,852
MyrbetriqMirabegron18$11,198
Tresiba Flextouch U-200Insulin Degludec12$10,328
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$6,032
Levothyroxine Sodium309$3,514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$365$138,410124 claims
Lilly USA, LLCMounjaro, Trulicity$31$95,83888 claims
Boehringer IngelheimJardiance, Stiolto Respimat$43$79,39865 claims
GSKTrelegy Ellipta, Breo Ellipta$25$31,86144 claims
MerckJanuvia$42$23,78530 claims
Johnson & JohnsonXarelto$61$18,89618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →